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Abstract: Coccidioidomycosis is a highly prevalent disease in the Western hemisphere. It is considered  one of the 
most	virulent	primary	fungal	infections.	Coccidioides	species	live	in	arid	and	semi-arid	regions,	causing	mainly	
pulmonary infection through inhalation of arthroconidia although many other organs can be affected. Primary 
inoculation	is	rare.	Since	the	first	case	of	coccidioidomycosis	was	reported	in	1892,	the	skin	has	been	identified	as	
an important target of this disease. Knowledge of cutaneous clinical forms of this infection is important and very 
useful for establishing prompt diagnosis and treatment. The purpose of this article is to provide a review of this 
infection,	emphasizing	its	cutaneous	manifestations,	diagnostic	methods	and	current	treatment.
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INTRODUCTION
Coccidioidomycosis,	 also	 known	 as	 “San	 Joa-
quin	 Valley	 Fever”	 or	 “Desert	 Rheumatism”,	 is	 the	
oldest	 of	 the	major	 systemic	mycoses,	 considered	 to	
be one of the most infectious fungal diseases.1,2 Two 
different	 species	 have	 been	 recognized	 as	 causative	
agents: Coccidioides immitis and C. posadasii. The 
former appears to be limited to Southern California 
and	 Northern	Mexico,	 while	 the	 latter	 occurs	 in	 all	
other endemic areas.1 It is almost exclusively preva-
lent	in	the	Western	Hemisphere,	mostly	in	semiarid	to	
arid	life	zones	of	Southwestern	United	States,	north	of	
Mexico,	and	some	places	in	Central	and	South	Amer-
ica.3 This fungal infection can cause a broad clinical 
spectrum:	it	can	be	asymptomatic,	or	it	can	range	from	
a mild febrile illness to severe pulmonary manifes-
tations or disseminated disease.4 In symptomatic pa-
tients,	the	most	common	manifestation	is	pulmonary	
disease,	 but	many	other	 organs	 can	be	 affected.	Cu-
taneous involvement of coccidioidomycosis entails a 
great	significance	because	of	its	wide	heterogeneity	of	
clinical manifestations that can confuse the clinician.
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HISTORICAL VIGNETTE
Coccidioidomycosis	was	first	described	in	1892	
by	Alejandro	Posadas	(a	medical	student	from	Argen-
tina),	when	he	evaluated	Domingo	Ezcurra,	a	soldier	
who presented with a verrucous papule on the right 
cheek.	A	diagnosis	of	mycosis	fungoides	with	psoros-
permia	was	considered.	After	having	observed	spheri-
cal	organisms	with	a	double-refractile	outer	wall,	that	
appeared	similar	 to	 the	protozoan	Coccidia,	Posadas	
and	his	mentor,	Robert	Wernicke,	believed	that	these	
organisms	had	a	parasitic	origin.	Ezcurra	died	in	1898	
despite many topical treatments. His head is now con-
served	in	a	museum	in	Buenos	Aires.5,6
Some	years	later,	Rixford	and	Gilchrist,	both	pa-
thologists,	analyzed	the	biopsies	of	two	similar	cases	
in	 California,	 involving	 emigrants	 from	 the	Azores,	
a	group	of	islands	belonging	to	Portugal,	finding	the	
same structures previously described by Posadas.5-7 In 
1896,	the	organism	was	given	the	names	Coccidioides	
(“resembling	 Coccidia”)	 and	 immitis	 (meaning	 “not	
mild”,	 since	 it	was	perceived	as	a	 lethal	disease).4 In 
1900,	Ophüls	and	Moffitt	defined	the	fungal	etiology	
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of this microorganism and established its dimorphism. 
In	1914,	Cooks	used	the	coccidioidin	test	for	the	first	
time and described the precipitin reaction. 8
In	1929,	the	fatal	outcome	in	patients	with	this	
disease	 was	 questioned	 after	 the	 report	 of	 Harold	
Chope’s	infection.	This	medical	student,	while	work-
ing	at	Stanford	University,	accidentally	inhaled	C.	im-
mitis	 spores	 and	 developed	 severe	 pneumonia,	 but,	
surprisingly,	he	survived	and	recovered	completely.	4,9
In	Mexico,	the	first	case	was	presented	in	1932	
by	 Cicero	 and	 Perrin;	 and	 later,	 in	 1945,	 González-
Ochoa described the Northern states of the country as 
endemic	zones,	by	 epidemiological	 testing	with	 coc-
cidioidin cutaneous reactions. 8
When	the	first	cases	were	reported,	coccidioido-
mycosis	was	considered	a	disfiguring,	fatal	illness,	but	
nowadays it is known that most cases follow a benign 
course,	 and	only	 around	 5%	of	 cases	 become	 symp-
tomatic and chronic. 5
ETIOLOGY
Coccidioidomycosis is caused by the dimor-
phic,	 soil-borne	ascomycete	 fungi.	 It	has	 two	known	
genetic species: C. immitis and C. posadasii. The for-
mer	seems	to	be	restricted	to	California,	Arizona,	and	
Baja	California	 (Mexico),	while	 the	 latter	 is	 found	 in	
the remaining endemic regions. Both species differ ge-
netically,	but	they	are	clinically	and	microbiologically	
indistinguishable. 10
GEOGRAPHY AND ECOLOGY
 Coccidioidomycosis is endemic in the Western 
hemisphere,	 particularly	 between	 the	 40°	 latitudes	
north	and	south.	There	are	two	predominant	regions,	
located in the Southwestern United States and the 
north	 of	 Mexico	 (Baja	 California,	 Chihuahua,	 Coa-
huila,	Nuevo	León	and	Tamaulipas,	 all	 of	 them	cor-
responding	to	the	Sonoran	Desert	zone).10,11	Other ar-
eas	have	been	described	in	central	states	of	Mexico,	as	
well	as	in	Central	and	South	America. 11
Coccidioides	spp.	are	found	in	alkaline,	sandy	
soils	from	semi-desert	regions	with	hot	summers,	gen-
tle	winters,	and	annual	rainfall	between	10	and	50	cm.	
These fungi are usually found 10 to 30 cm beneath the 
surface.4,12
Different types of cactus and bushes like Lar-
rea	 tridentata	 (“creosote	bush”)	have	been	 identified	
as common vegetation in the type of soil where this 
fungus lives. 5
EPIDEMIOLOGY
It	is	estimated	that	150,000	new	infections	occur	
annually in areas of the Southwestern United States. 
Coccidioidomycosis is not a nationally reportable dis-
ease (it is only reported in the states of California and 
Arizona),	therefore,	the	exact	national	incidence	is	un-
known.1
The incidence of Coccidioides spp. infection has 
increased in recent years. In a recent summary by the 
California	Department	 of	Health,	 it	 rose	 from	 4.3	 to	
11.6	per	 100,000	population	 from	2001	 to	 2010.	 3,13	In 
Arizona,	it	rose	from	12	to	58.2	per	100,000	population	
over the same time period.3,14	Overall,	 it	 is	estimated	
that	70%	of	all	Coccidioidomycosis	cases	in	USA	occur	
in	Arizona,	and	25%	in	California.15
In	Latin	America	there	are	no	reliable	statistics.	
In	Mexico,	Coccidioidomycosis	is	not	a	reportable	dis-
ease	and	its	true	incidence	is	unknown,	though	most	
clinical case reports originate in the northern region 
of the country. Regional skin test surveys with coccid-
ioidin in Mexico have shown positive skin reactions 
between	 10%	 (in	 Tijuana	 and	 Baja	 California,	 1991)	
and	93%	(in	Coahuila,	2005).11,16,17	Historically,	Argen-
tina	 is	of	great	 interest,	 since	 it	was	 the	place	where	
the	first	 case	of	Coccidioidomycosis	was	 reported	 in	
1892. Even though the magnitude of infection in this 
country	 is	 unknown,	 a	 prevalence	 from	 14.8	 to	 16%	
has been estimated according to some coccidioidin 
surveys.1,18,19
The	 exponential	 rise	 in	 Coccidioidomycosis,	
particularly	in	endemic	places,	has	been	attributed	to	
many	factors,	including	a	growing	population,	migra-
tion	of	susceptible	people	to	endemic	areas,	an	increase	
in individuals of advanced age or with immunosup-
pression,	soil	disturbances	caused	by	construction	and	
businesses,	and	climate	changes.10,14,20
RISK FACTORS FOR INFECTION
The most important risk factor is dust exposure 
in	 endemic	 areas,	 usually	 due	 to	 occupational	 and	
recreational activities.1 Populations at greater risk for 
infection are those with intense exposure to aerosol-
ized	arthroconidia,	including	agricultural	or	construc-
tion	 workers,	 or	 people	 who	 participate	 in	 outdoor	
activities such as hunting or digging in the soil.4,21,22	
Oubreaks of coccidioidomycosis have been described 
in	 military	 personnel	 training	 in	 endemic	 areas,	 ar-
madillo	hunting	expeditions,	construction	work,	and	
model airplane competitions.23-25 Other risk factors in-
clude	natural	disasters	such	as	earthquakes	and	wind-
storms.4,26	
Coccidioidomycosis	 affects	 all	 age	 groups,	
though higher incidence rates have been document-
ed	among	adults,	ranging	from	40-49	years	in	Califor-
nia,	 to	 >65	 years	 in	Arizona.14,27	It has a predilection 
for men over women (with an estimated incidence of 
54%	 versus	 46%	 of	 cases	 in	Arizona,	 respectively).28 
Gender disparities are thought to be mostly related 
to occupational factors (since men tend to participate 
more	in	high	risk,	outdoor	activities);	however,	males	
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also	have	greater	risk	for	dissemination,	suggesting	a	
hormonal or genetic component.1,29
Certain groups are considered more vulnerable 
to coccidioidal infection. Racial predilection for Fili-
pino	or	African	American	patients	has	been	reported.	
30,31	These groups have higher rates for infection and 
dissemination	of	disease,	ranging	from	10	to	175	times	
higher than other ethnicities.32 Pregnant women are 
also considered a high risk group for severe or dis-
seminated	 disease,	 especially	 during	 later	 stages	 of	
pregnancy	 (usually	 during	 the	 third	 trimester),	 pre-
sumably associated with immunologic and hormon-
al factors.33,34	 Immunosuppressed	 patients,	 predomi-
nantly	 those	with	alteration	of	T	cell	 function,	are	at	
higher risk of infection and dissemination of disease. 
This group includes patients with human immunode-
ficiency	 virus	 (HIV),	 hematologic	malignancies	 such	
as	 non-Hodgkin	 lymphoma	 (NHL)	 or	 chronic	 lym-
phocytic	leukemia	(CLL),	inflammatory	arthritis,	and	
diabetes.32,35-37	Organ	 transplantation	 and	 subsequent	
use of immunosuppressive agents have also been de-
scribed as important risk factors for the disease. 1
MICROBIOLOGY, LIFE CYCLE AND IMMUNOLOGY
Coccidioides species exist in two phases: the 
mycelial	phase,	and	the	spherule	phase.	(12)They	are	
found	as	mycelia	in	the	soil,	made	of	septate	and	ram-
ified	 hyphae,	which	 proliferate	 rapidly	 after	 a	 rainy	
period.	 Then,	 as	 the	 environment	 dries,	 mycelia	 re-
produce	 asexually,	 breaking	 the	 hyphae	 and	 releas-
ing	 small,	 thick-walled	 spores	 named	 arthroconidia.	
These	 spores	 can	 spread	 from	 the	 soil	by	wind,	nat-
ural	disasters,	and	human	activities.	 Infection	occurs	
with	the	inhalation	of	arthroconidia,	which	later	reach	
the	 human	 bronchioles	 and	 alveoli.	 There,	 they	 can	
enlarge	 and	 form	 spherules,	which	 develop	 internal	
endospores. The endospores are released and spread 
to nearby or distant tissues and can develop again into 
spherules,	continuing	their	life	cycle.10,38-40
Immunological aspects are complex and in-
volve the participation of many cell types. The acute 
immunologic response to infection consists mainly 
of	an	early	influx	of	polymorphonuclear	neutrophils,	
monocytes and natural killer cells; eosinophilia may 
also	be	present	during	this	phase.	During	a	later	stage,	
a	granulomatous	reaction	may	develop,	with	increased	
number	of	lymphocytes,	plasma	cells	and	multinucle-
ated giant cells. Other immune mechanisms involve 
the presentation of coccidioidal antigens by dendrit-
ic	cells,	the	activation	of	B	lymphocytes	and	CD4+	T	
lymphocytes,	and	the	development	of	a	delayed-type	
hypersensitivity and cellular immunity.10,40,41	Once de-
veloped,	 cellular	 immunity	 appears	 to	 be	 protective	
and long lived. 41
CLASSIFICATION AND CLINICAL PICTURE
Coccidioidomycosis may cause a heteroge-
neous	clinical	spectrum	and	be	classified	into	primary	
and secondary disease. Primary disease generally af-
fects	the	lungs,	which	is	by	far	the	most	common	site	
involved.	In	this	case,	 it	 is	acquired	by	direct	 inhala-
tion of arthroconidia. Primary involvement of the skin 
is	 quite	uncommon.	 It	 is	 acquired	by	direct	 inocula-
tion of the fungus by means of splinters and abrasions. 
Secondary disease can affect the lungs and become a 
chronic	process.	On	the	other	hand,	disseminated	dis-
ease (usually resulting from hematogenous spread of 
a	 primary	 lung	 infection)	 can	 involve	many	 organs,	
among	 them:	 the	skin,	bones,	 joints,	nervous	system	
and meninges. 8
PULMONARY COCCIDIOIDOMYCOSIS
Primary pulmonary coccidioidomycosis is the 
most	common	infection.	Up	to	60%	of	the	affected	in-
dividuals	are	usually	asymptomatic,	and	the	remain-
ing	 40%	 can	 present	 with	 pulmonary	 and	 systemic	
manifestations that usually appear one to three weeks 
after inhalation of arthroconidia. 12,42	Most symptom-
atic	 patients	 can	develop	 a	flu-like	 syndrome	 (fever,	
headache,	 profound	 fatigue,	 cough,	 pleuritic	 pain,	
and	arthralgias),	commonly	known	as	“The	Valley	Fe-
ver	of	San	Joaquin”.42 Cough	and	fever	appear	in	75%	
of	patients;	 the	skin	is	affected	in	up	to	50%	of	cases	
during	this	acute	phase,	most	commonly	in	the	form	
of	 a	 non-pruritic	 papular	 rash,	 erythema	 nodosum,	
and erythema multiforme. 1 Radiographically,	 it	may	
be	similar	to	other	forms	of	pneumonia,	showing	lobar	
segmental	or	subsegmental	infiltrates.	Hilar	adenopa-
thy and pleural effusions may also be observed. 43
Chronic and progressive pneumonia may occur 
in a small percentage of cases. The patients present 
symptoms that last for more than 3 months (persistent 
cough,	hemoptysis,	and	weight	loss).	Radiographical-
ly,	cavitations	and	solitary	pulmonary	nodules	are	de-
tected. 38
 
DISSEMINATED COCCIDIOIDOMYCOSIS
Disseminated	disease	occurs	in	1%	to	5%	of	all	
patients	affected	by	coccidioidomycosis,	and	it	usual-
ly is clinically manifested within 2 years of exposure. 
Dissemination	can	affect	any	organ,	with	the	skin,	cen-
tral nervous system and musculoskeletal system being 
reported as the most prevalent. 12 Many different cu-
taneous manifestations may be seen in disseminated 
disease and will be reviewed in detail later on this ar-
ticle. Osteoarticular infection is usually monoarticular 
(affecting	the	knee)	or	it	can	affect	the	vertebrae.	These	
can	be	difficult	to	treat.	44 Central nervous system in-
volvement most commonly presents as meningeal 
infection,	which	can	be	fatal	 if	 left	untreated	(95%	of	
patients	die	within	2	years	of	diagnosis),	and	requires	
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life-long therapy.	45,46
Some factors that entail a higher risk for dissem-
ination	of	coccidioidomycosis	are	Filipino	and	African	
patients,	 HIV/AIDS,	 organ	 transplantation,	 use	 of	
immunosuppressive	medications,	older	age,	diabetes	
and late-stage pregnancy. 4,31,33,37
COCCIDIOIDOMYCOSIS AND THE SKIN
Since	the	first	described	case	of	coccidioidomy-
cosis	 in	Argentina,	 cutaneous	 involvement	 has	 been	
present.	Among	 the	organs	most	 commonly	affected	
after	pulmonary	infection,	the	skin	is	often	involved.	
Due	to	the	wide	variety	of	clinical	presentations,	this	
disease may be included in the group of “great imita-
tors”. Knowledge and evaluation of cutaneous man-
ifestations	 could	 be	 of	 great	 utility	 and	 significance	
for accurate and early diagnosis and treatment of this 
disease. 47
CUTANEOUS MANIFESTATIONS OF COCCIDIOIDOMY-
COSIS
Skin manifestations can be seen in three differ-
ent	scenarios	of	coccidioidal	infection:	1)they	can	be	a	
part of the acute pulmonary infection and present as 
an	 “acute	pulmonary	 exanthema”;	 2)they	 can	 reflect	
the presence of a disseminated infection (secondary 
cutaneous	infection);	or,	in	rare	occasions,	3)they	can	
represent a primary infection due to direct inoculation 
(primary	cutaneous	infection).	Despite	their	variabili-
ty	and	heterogeneity,	 cutaneous	manifestations	of	C. 
immitis differ between these three forms of disease. 8
 Cutaneous manifestations can be further cate-
gorized	as	reactive	and	organism-specific.	 48 Reactive 
manifestations	do	not	contain	visible	microorganisms,	
and occur during acute primary pulmonary infection 
in	up	to	50%	of	patients.	49 They include erythema no-
dosum,	erythema	multiforme,	acute	generalized	exan-
thema,	 reactive	 interstitial	 granulomatous	dermatitis	
and Sweet’s syndrome. 47 Organism-specific	manifes-
tations	present	with	lesions	that	contain	the	organism,	
which	can	be	identified	in	cultures	or	histopathology;	
they result from hematogenous spread of a primary 
pulmonary	 infection	 (secondary	 cutaneous	 disease)	
or,	very	rarely,	as	a	result	of	direct	trauma	to	the	skin	
(primary	cutaneous	disease). 49
REACTIVE CUTANEOUS MANIFESTATIONS 
ERYTHEMA  NODOSUM
Erythema nodosum is considered the most fre-
quent	 reactive	 cutaneous	 manifestation,	 appearing	
one to three weeks after the initial respiratory symp-
toms. 50,51	It	is	a	self-limited,	inflammatory	disorder	of	
the	 skin	 and	 subcutaneous	 tissues	 characterized	 by	
multiple	erythematous,	painful	nodules	usually	limit-
ed	to	the	extremities	(Figure	1).52 Gender and ethnicity 
play an important role in the onset of erythema nodo-
sum;	it	is	more	commonly	seen	in	white	females,	and	
it	is	rare	in	African	American	men.53 In some endemic 
sites,	 in	 the	presence	of	erythema	nodosum,	Coccid-
ioides must be ruled out.50,54	 It represents a delayed 
hypersensitivity	 reaction	 (cell-mediated	 immunity)	
which may confer protection against the organism.55 
It is associated with a favorable prognosis (with less 
dissemination	 and	 chronicity	 rates).	 Histologically,	
septal	 fibrosis,	 thickened	 vessels	 with	 mononuclear	
cells	in	fat	lobules	and	focal	granulomatous	inflamma-
tion with occasional multinucleated giant cells may be 
seen,	and	no	pathogens	are	found	within	the	specimen	
(Figure	2).56 
ERYTHEMA MULTIFORME
Erythema multiforme is another cutaneous 
manifestation that has been reported since a long time 
ago in association with coccidioidomycosis. It is char-
acterized	 by	 target-like	 lesions	 that	 typically	 occur	
within	the	first	48	hours	of	the	initial	symptoms	and	
apparently	 reflect	 a	 hypersensitivity	 response	 to	 the	
infection	(Figure	3).	49 Oral	involvement,	pruritus	and	
palmar	 desquamation	 have	 also	 been	 described	 as	
Figure 1:	Erythema	nodosum,	considered	the	most	frequent	
reactive manifestation and commonly involving 
the lower extremities
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part of this manifestation.57 It is unclear whether true 
erythema multiforme occurs in coccidioidomycosis or 
if it actually represents part of an acute exanthema or 
Sweet’s	syndrome,	although	EM-like	lesions	must	be	
taken into consideration when evaluating a case sug-
gesting coccidioidomycosis.47
ACUTE EXANTHEMA
A	generalized	 exanthema	 or	 “toxic	 erythema”	
can	occur	in	approximately	10	to	12%	of	patients	with	
symptomatic pulmonary coccidioidomycosis and 
it	has	been	reported	 in	up	to	50%	to	60%	of	patients	
during	outbreaks.	 It	usually	appears	during	 the	first	
An Bras Dermatol. 2015;90(5):610-21.
days	of	symptoms	as	papular,	macular,	urticarial,	tar-
get-like or morbiliform lesions which may be pruritic 
and last for several weeks.57 Clinically,	it	may	be	mis-
taken for allergic contact dermatitis or erythema mul-
tiforme,	and	histopathological	findings	show	a	mixed	
inflammatory	infiltrate	with	perivascular	distribution	
that can also mislead the diagnosis.5,57,58	The exanthe-
ma	usually	resolves	before	medical	evaluation,	though	
it may persist for several weeks and occasionally be 
followed	by	desquamation	of	the	palms.49,57
 
SWEET’S SYNDROME
Sweet’s	 Syndrome,	 also	 called	 “acute	 febrile	
neutrophilic dermatosis” has been reported as a very 
rare	 feature	 of	 coccidioidomycosis,	 with	 few	 cases	
reported in the literature.59,60	It	 is	characterized	by	an	
acute	 eruption,	 consisting	 of	 painful	 erythematous,	
well-demarcated	papules	and	plaques,	 in	association	
with fever and neutrophilic leukocytosis. In some cas-
es,	vesicles	and	pustules	can	be	seen.	The	common	to-
pography	 involves	 the	 arms,	 face	 and	neck,	 and	 the	
biopsy	specimen	shows	a	diffuse	 inflammatory	 infil-
trate	 in	 the	dermis,	with	neutrophils	 and	 leukocyto-
clastic debris. Even though the mainstay of treatment 
for	Sweet’s	syndrome	are	corticosteroids,	they	are	not	
recommended	in	the	setting	of	coccidioidal	infection,	
since they could exacerbate the condition.60
INTERSTITIAL GRANULOMATOUS DERMATITIS
Granulomatous tissue reactions have been 
described as a reactive manifestation of a variety of 
systemic diseases. Interstitial granulomatous derma-
titis has been reported in 5 patients with pulmonary 
coccidioidomycosis. This eruption resembles Sweet’s 
syndrome	 or	 a	 disseminated	 infection,	 with	 edema-
tous	and	indurated	cutaneous	papules,	nodules,	and	
plaques	 presenting	 at	 the	 beginning	 of	 the	 illness.	
Macrophages,	eosinophils,	neutrophils	and	leukocyto-
clastic debris are seen in the biopsy. Resolution of the 
lesions	occurs	in	a	variable	period	of	time,	from	days	
to two months. 48
ORGANISM-SPECIFIC MANIFESTATIONS
SECONDARY CUTANEOUS DISEASE (DISSEMI-
NATED COCCIDIOIDOMYCOSIS)
	 The	 skin	 has	 been	 recognized	 as	 one	 of	 the	
most common sites of disseminated coccidioidomy-
cosis,	and	it	 is	estimated	that	15%	to	67%	of	patients	
with disseminated disease have skin involvement.  49 
The clinical appearance of lesions is widely heteroge-
neous,	including	papules,	nodules,	gummas,	pustular	
acneiform	 lesions,	 ulcerated	 and	 verrucous	 plaques,	
scars,	abscesses	and	fistulae	 (Figures	4-7).5 The usual 
finding	 are	 the	 nodules. 42  The topography involves 
the	 face,	 neck,	 scalp,	 and	 chest	 wall.5,61	The nasola-
Figure 2: Histopathologic image of erythema nodosum in a patient 
with coccidioidomycosis. No organisms were found within the 
specimen
Figure 3: Erythema multiforme: another common cutaneous mani-
festation	of	coccidioidomycosis,	characterized	by	target-like	lesions
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bial fold is a common site of infection.62-64 Facial le-
sions have been associated with meningitis in some 
patients.65 Cutaneous lesions typically present within 
several	weeks	or	months	after	 the	primary	infection,	
or they can be the initial manifestation of the disease. 
53,63	They may be solitary or multiple and are usually 
asymptomatic.47 Important differential diagnosis in-
clude	 histoplasmosis,	 blastomycosis,	 cryptococcosis,	
tuberculosis,	 sarcoidosis	 and	 primary	 skin	 malig-
nancies.42 Histopathology	 findings	 are	 variable,	 but	
usually show suppurative granulomas that contain 
double-walled	refractile	spherules	(10	to	80	µm)	with	
endospores	(Figure	8).	62
 
PRIMARY CUTANEOUS COCCIDIOIDOMYCO-
SIS
	Primary	cutaneous	infection	is	extremely	rare,	
with about 25 cases previously reported in the litera-
ture	since	1926.	It	 is	usually	seen	in	adults,	although	
a few cases have been reported in children.66 It results 
from direct traumatic inoculation of the organism into 
the skin by an external source and typically manifests 
as	a	painless,	indurated	nodule	with	ulceration	(chan-
croid	 lesion)	 on	 an	 extremity.5 Secondary nodules 
may arise in a linear lymphatic sporotrichoid distri-
bution	 (Figure	 9).67 In	 1953,	Wilson	 et	 al	 established	
diagnostic criteria for primary cutaneous coccidioi-
domycosis,	including:	absence	of	pulmonary	disease,	
Figure 4: Disseminated coccidioidomycosis presenting as an 
erythematous,	crusted	plaque	in	the	upper	extremity
Figure 6: In	this	patient,	disseminated	coccidioidomycosis	
presented as an ulcerated nodule on the face
Figure 7: Disseminated coccidioidomycosis presenting as an 
erythemato-squamous	plaque	on	the	upper	chest
Figure 5:	Verrucous	plaques	are	also	a	common	manifestation	of	
disseminated coccidioidomycosis
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clear	evidence	of	traumatic	inoculation,	an	incubation	
period	 of	 1	 to	 3	weeks,	 a	 chancriform	 lesion	with	 a	
painless,	ulcerated	nodule	or	plaque;	an	early	positive	
precipitin	reaction,	an	early	positive	coccidioidin	skin	
test,	a	negative	or	 low	complement	fixation	reaction,	
the presence of lymphadenopathy and sporotrichoid 
nodules,	and	spontaneous	healing	after	some	weeks.68 
Presence of granulomas containing the spherules of 
the fungus is observed. Prognosis of this form of coc-
cidioidomycosis	is	often	excellent,	usually	with	spon-
taneous resolution. 69
DIAGNOSTIC METHODS
Culture,	 microscopy	 and	 serology	 have	 been	
the mainstay for diagnosis of coccidioidomycosis. 70 
Other	diagnostic	 tools	 such	as	 cutaneous	 tests,	PCR,	
and imaging studies are also used. 5 
CULTURE AND MICROSCOPY
C. immitis and C. posadasii grow in several 
culture	 media,	 such	 as	 brain-heart	 infusion,	 Sab-
ouraud-dextrose,	 blood	 and	 chocolate	 agar.	 Growth	
can	 be	 fast,	 from	 2-7	 days,	 or	 take	 up	 to	 2-3	weeks.	
They	grow	at	 room	 temperature	 as	 a	white,	 cottony	
mold	(Figure	10). 5
Spherules	may	be	identified	by	direct	mycology	
examination of the specimen (with potassium 
hydroxide	 and	 calcofluor)	 (Figure	 11).	 The	 presence	
of	 septate	 hyphae,	 barrel-shaped	 arthroconidia,	 and	
double-walled refractile spherules measuring 10-
80 µm with endosporulation is characteristic. Some 
stains	like	hematoxylin	and	eosin,	periodic	acid-Schiff	
and Gromori-Grocott can enhance the sensitivity for 
identification.5(Figure	12)
SEROLOGY
Serologic tests identifying anticoccidioidal anti-
bodies	(IgM	and	IgG)	are	the	most	frequently	employed	
assays for the diagnosis and prognosis of coccidioido-
mycosis.	These	 tests	are	highly	specific	and	relatively	
sensible.	They	include	tube	precipitin	(TP)	and	comple-
ment	fixation	(CF)	assays,	as	well	as	immunodiffusion	
tube	precipitin	 (IDTP)	 and	 immunodiffusion	 comple-
ment	fixation	(IDCF),	which	are	variants	of	these	assays	
that employ immunodiffusion in agar. 1
IgM	 antibodies	 appear	 between	 the	 first	 and	
third weeks after the initial symptoms. TP and IDTP 
tests are the most used methods for detecting IgM an-
tibodies.	 They	 are	 positive	 usually	 between	 the	 first	
and third weeks of infection.1 A	positive	test	may	indi-
Figures 8: Biopsy specimen showing a Coccidioides spherule
Figures 10: 
Coccidioidomycosis 
culture:	white,	 cottony	
mold
Figures 9: Primary coccidioidomycosis presenting as lesions in a 
typical sporothricoid pattern
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cate a primary infection or reactivation. IgM antibod-
ies tend to disappear after 4 months. 69
CF	 and	 IDCF	 tests	 detect	 complement-fixing	
IgG antibodies. They appear 8-10 weeks after the ini-
tial	 symptoms,	 and	 last	 longer	 than	 tube	 precipitin	
antibodies. Titers greater than 1:32 indicate active dis-
seminated disease. The titers usually correlate with 
severity;	they	have	prognostic	significance	and	can	be	
used to follow progress during treatment. These anti-
bodies tend to disappear after 6 to 8 months.69
In	summary,	a	positive	TP	or	IDTP	test,	with	a	
negative	or	low	CF	or	IDCF	test,	suggests	primary	dis-
ease.	On	the	other	hand,	a	negative	TP	or	 IDTP	test,	
with a high titer of CF or IDCF suggests disseminated 
disease. 71
Figures 11: Direct microscopy study of coccidioidomycosis
Figures 12: Gomori-Grocott stain
OTHER METHODS
Molecular	techniques	such	as	in situ	hybridiza-
tion	(ISH)	and	polymerase	chain	reaction	(PCR)	may	
assist in the diagnosis of coccidioidomycosis. They are 
not widely available and their sensitivity has not been 
determined	(it	may	range	from	80	to	98%,	depending	
on	the	specimen	site).	70,72
Skin testing is a diagnostic method that can 
evaluate the overall incidence of coccidioidomycosis 
in	endemic	areas.	However,	its	use	is	limited,	since	a	
positive skin test does not distinguish between current 
or previous infection.47
TREATMENT
Three important factors must be taken into con-
sideration when treating coccidioidomycosis: the severi-
ty	of	pulmonary	infection,	the	presence	or	absence	of	dis-
semination,	and	the	patient’s	individual	risk	factors.47,73
 Not every patient with coccidioidomycosis 
needs	 to	 be	 treated.	 In	 fact,	 pulmonary	 coccidioido-
mycosis is often self-limited and some authors do not 
indicate treatment for immunocompetent patients 
without risk factors for dissemination.1 However,	fol-
lowing	the	availability	of	triazoles,	most	clinicians	fa-
vor treating all symptomatic patients with antifungal 
therapy; some of them claim that early treatment may 
reduce	symptom	duration	and	risk	of	dissemination,	
though there is no evidence for this assertion.	3,74
 For primary pulmonary coccidioidomyco-
sis,	 immunocompetent	 patients	 without	 risk	 factors	
for	 dissemination	 may	 be	 treated	 with	 fluconazole	
or	itraconazole	at	doses	of	400	mg	per	day,	for	3	to	6	
months. Patients with severe symptoms lasting more 
than	 6	weeks,	 or	with	 risk	 factors	 for	 dissemination	
(immunosuppression,	 AIDS,	 African-American,	 Fili-
pino,	pregnant	women	and	comorbidities)	should	also	
be	treated.	In	pregnant	women,	the	mainstay	of	treat-
ment	is	amphotericin	B	(due	to	azoles	teratogenicity).	
All	 other	 patients	 with	 primary	 coccidioidomycosis	
and risk factors for dissemination will be treated with 
azole	therapy:	fluconazole	or	itraconazole	at	doses	of	
400 mg per day for 4 to 12 months.3,73
 In cases of chronic pulmonary coccidioidomyco-
sis,	fluconazole	or	itraconazole	at	doses	of	400	mg	per	
day	for	12	to	18	months	or	more	are	indicated,	accord-
ing to clinical response. Severe or refractory infections 
may	be	treated	with	amphotericin	B,	deoxycholate	and	
liposomal forms.3,73	Posaconazol	and	voriconazol	have	
been successful in treating some cases.11,75
 Disseminated,	meningeal	forms	of	coccidioido-
mycosis	require	life-long	treatment	with	drugs	such	as	
fluconazole	400	mg	per	day	(with	initial	doses	of	up	
to	1000	mg	per	day)	or	itraconazole	400	to	600	mg	per	
day. Intrathecal amphotericin has also been indicated.
Disseminated,	 non-meningeal	 forms	 of	 coc-
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cidioidomycosis	 should	 be	 treated	 with	 fluconazole	
or	itraconazole	at	doses	of	400	mg	per	day	for	3	to	6	
months,	with	the	alternative	of	using	amphotericin	B	
in severe or rapidly progressing cases. In addition to 
medical	treatment,	surgical	debridement	of	abscesses	
is indicated if needed.73
 It	is	important	to	mention,	however,	that	anti-
fungal therapy has no role in the treatment of hyper-
reactive skin changes.49 In cases of primary cutane-
ous	 coccidioidomycosis,	 treatment	with	 itraconazole	
has	been	described,	at	doses	of	400	mg	per	day	for	6	
months with excellent response.76
CONCLUSION
Skin involvement is one of the most common 
extrapulmonary manifestations of coccidioidomyco-
sis. It involves a wide spectrum of clinical pictures. 
Recognizing	 them	 is	 very	 important	 to	 achieve	 a	
prompt and accurate diagnosis and treatment.q
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